Menu Menu


GSK Financials       Clear


GSK        0001131399    
Filing Date Form Type Description Document
2026-11-02 6-K TOTAL VOTING RIGHTS View Document
2026-10-28 6-K 3RD QUARTER RESULTS View Document
2026-10-26 6-K RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA View Document
2026-10-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-10-26 6-K JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE View Document
2026-10-26 6-K POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER View Document
2026-10-21 6-K US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B View Document
2026-10-19 6-K JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER View Document
2026-10-19 6-K RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER View Document
2026-10-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-10-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-10-13 S-8 S-8 View Document
2026-10-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-10-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-10-08 6-K WENDY BECKER CBE - NEW DIRECTORSHIP View Document
2026-10-06 6-K ADMISSION TO TRADING View Document
2026-10-01 6-K TOTAL VOTING RIGHTS View Document
2026-09-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-22 CERT NYSE CERTIFICATION View Document
2026-09-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-15 8-A12B 8-A12B View Document
2026-09-15 6-K 6-K View Document
2026-09-15 6-K GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA View Document
2026-09-14 6-K RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA View Document
2026-09-14 6-K JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC View Document
2026-09-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-10 424B2 424B2 View Document
2026-09-10 6-K JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE View Document
2026-09-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-09 FWP FWP View Document
2026-09-08 424B2 424B2 View Document
2026-09-08 6-K 6-K View Document
2026-09-01 6-K TOTAL VOTING RIGHTS View Document
2026-09-01 6-K MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III View Document
2026-08-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-08-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-08-24 6-K FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN View Document
2026-08-24 6-K US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER View Document
2026-08-20 144 View Document
2026-08-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-08-13 SCHEDULE 13G/A View Document
2026-08-13 13F-HR View Document
2026-08-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-08-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-08-03 6-K TOTAL VOTING RIGHTS View Document
2026-07-30 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-07-28 6-K NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE View Document
2026-07-28 6-K HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ View Document
2026-07-28 6-K 2ND QUARTER RESULTS View Document
2026-07-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-07-24 6-K ADMISSION TO TRADING View Document
2026-07-22 6-K JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS View Document
2026-07-20 6-K BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE View Document
2026-07-17 6-K AUDIT TENDER CONCLUSION View Document
2026-07-17 6-K CAMLIPIXANT PHASE III RESULTS UPDATE View Document
2026-07-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-07-15 6-K GSK COMPLETES ACQUISITION OF NUVALENT, INC View Document
2026-07-15 SC TO-T/A SC TO-T/A View Document
2026-07-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-07-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-07-13 6-K POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER View Document
2026-07-10 SC TO-T/A SC TO-T/A View Document
2026-07-10 6-K HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ View Document
2026-07-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-07-09 6-K DIRECTORATE CHANGE View Document
2026-07-07 SC TO-T/A SC TO-T/A View Document
2026-07-01 6-K TOTAL VOTING RIGHTS View Document
2026-06-29 6-K TRANSACTION IN OWN SHARES View Document
2026-06-29 6-K HOLDING(S) IN COMPANY View Document
2026-06-26 6-K HOLDING(S) IN COMPANY View Document
2026-06-24 SC TO-T/A SC TO-T/A View Document
2026-06-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-06-24 6-K GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT View Document
2026-06-24 SC TO-T SC TO-T View Document
2026-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-06-22 6-K TRANSACTION IN OWN SHARES View Document
2026-06-17 11-K 11-K View Document
2026-06-17 11-K 11-K View Document
2026-06-17 6-K CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA View Document
2026-06-15 6-K TRANSACTION IN OWN SHARES View Document
2026-06-12 6-K MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS View Document
2026-06-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-06-10 SC TO-C SC TO-C View Document
2026-06-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-06-09 SC TO-C SC TO-C View Document
2026-06-09 6-K DR HAL BARRON - NEW DIRECTORSHIP View Document
2026-06-09 SC TO-C SC TO-C View Document
2026-06-09 6-K GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. View Document
2026-06-08 6-K TRANSACTION IN OWN SHARES View Document
2026-06-01 6-K TOTAL VOTING RIGHTS View Document
2026-06-01 6-K TRANSACTION IN OWN SHARES View Document
2026-05-28 6-K POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN View Document
2026-05-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-05-26 SD SPECIALIZED DISCLOSURE REPORT View Document
2026-05-26 6-K ADMISSION TO TRADING View Document
2026-05-26 6-K TRANSACTION IN OWN SHARES View Document
2026-05-22 6-K Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026 View Document
2026-05-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299